Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oscotec's SYK Inhibitor Program Gets Korea Drug Fund Money

This article was originally published in PharmAsia News

Executive Summary

Oscotec is set to accelerate the development of a novel oral rheumatoid arthritis drug, helped by financial support from the state-run Korea Drug Development Fund for a US Phase I clinical trial of the South Korean venture’s spleen tyrosine kinase inhibitor.

You may also be interested in...



2022 Korean VC Financings Led By Mid-Stage Bioventures

Amid a generally harsh environment, venture capital investors in South Korea appeared to take a more selective approach in 2022, with more established and financially stable domestic bioventures the biggest beneficiaries.

Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly

The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.

From Science To Commercialization: How Genexine Is Making The Shift

Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC089239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel